Iranian
Biomedical Journal
Volume 26, Issue 6 (11-2022)
IBJ 2022, 26(6): 406-413 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Issares V, Milas G P, Zareifopoulos N. Antitumorigenic Effect of Cannabidiol in Lung Cancer: What Do We Know So Far?–A Mini Review. IBJ 2022; 26 (6) :406-413
URL: http://ibj.pasteur.ac.ir/article-1-3732-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3732-en.html
Abstract:
Lung cancer remains a major factor contributing to morbidity and mortality worldwide. cannabidiol (CBD) and Δ9-tetrahydrocannabinol could serve as a specific treatment for lung cancer, owing to their essential role in lung cancer cell apoptosis. This review evaluated the antitumorigenic mechanisms of CBD in lung cancer cells. We searched the databases MEDLINE, clinicaltrials.gov, Cochrane Central Register of Controlled Trials, and Google Scholar using specific terms. Of 246 studies screened, nine were included and assessed using the ToxRTool. All the selected studies were conducted in vitro, and four of which also had an in vivo content. The most common cell line used in all the studies was A549; however, some studies contained other cell lines, including H460 and H358. Our findings suggested that CBD has direct antineoplastic effects on lung cancer cells through various mechanisms mediated by cannabinoid receptors or independent of these receptors. All studies were referred to an in vitro model; hence, further research in animals is required.
Type of Study: Review Article |
Subject:
Cancer Biology
References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA 2021; 71(1): 7-33. [DOI:10.3322/caac.21654]
2. Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer epidemiology, biomarkers and prevention 2019; 28(10): 1563. [DOI:10.1158/1055-9965.EPI-19-0221]
3. Underner M, Urban T, Perriot J, De Chazeron I, Meurice JC. Cannabis smoking and lung cancer. Revue des Maladies respiratoiresr 2014; 31(6): 488-498. [DOI:10.1016/j.rmr.2013.12.002]
4. Schwartz AG, Cote ML. Epidemiology of lung cancer. Advances in experimental medicine and biology 2016; 893: 21-41. [DOI:10.1007/978-3-319-24223-1_2]
5. Cao C, Manganas C, Ang SC, Peeceeyen S, Yan TD. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interactive cardiovascular and thoracic surgery 2013; 16(3): 244-249. [DOI:10.1093/icvts/ivs472]
6. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Walter J, Curran J, Wu YL, Paz-Ares L. Seminar Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389(10066): 299-311. [DOI:10.1016/S0140-6736(16)30958-8]
7. Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. Journal of hematology and oncology 2019; 12: 1-11. [DOI:10.1186/s13045-019-0736-3]
8. Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surgical pathology clinics 2020; 13(1):17-33 [DOI:10.1016/j.path.2019.11.002]
9. Lim RBL. End-of-life care in patients with advanced lung cancer. Therapeutic advances in respiratory disease 2016; 10(5): 455-467. [DOI:10.1177/1753465816660925]
10. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. International journal of obesity 2006; 30: S13-S18. [DOI:10.1038/sj.ijo.0803272]
11. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and therapeutics 1997; 74(2): 129-180. [DOI:10.1016/S0163-7258(97)82001-3]
12. Amin MR, Ali DW. Pharmacology of medical cannabis. Advances in experimental medicine and biology 2019; 1162: 151-165. [DOI:10.1007/978-3-030-21737-2_8]
13. Birdsall SM, Birdsall TC, Tims LA. The use of medical marijuana in Cancer. Current oncology reports 2016; 18(7): 1-9. [DOI:10.1007/s11912-016-0530-0]
14. Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C. Cannabidiol-from plant to human body: A promising bioactive molecule with multi-target effects in cancer. International journal of molecular sciences 2019; 20(23): 5905. [DOI:10.3390/ijms20235905]
15. Kyriakou I, Yarandi N, Polycarpou E. Efficacy of cannabinoids against glioblastoma multiforme: A systematic review. Phytomedicine 2021; 88: 153533. [DOI:10.1016/j.phymed.2021.153533]
16. Klimisch HJ, Andreae M, Tillmann U. A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. Regulatory toxicology and pharmacology 1997; 25(1): 1-5. [DOI:10.1006/rtph.1996.1076]
17. Liew KL, Capuano E, Yung B. Lung cancer patient who had declined conventional cancer treatment: could the self-administration of 'CBD oil' be contributing to the observed tumour regression? BMJ case reports 2021; 14(10): e244195. [DOI:10.1136/bcr-2021-244195]
18. Sulé-Suso J, Watson NA, van Pittius DG, Jegannathen A. Striking lung cancer response to self-administration of cannabidiol: A case report and literature review. SAGE open medical case reports 2019; 7: 2050313X1983216. [DOI:10.1177/2050313X19832160]
19. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. British journal of clinical pharmacology 2013; 75(2): 303-312. [DOI:10.1111/j.1365-2125.2012.04298.x]
20. Jett J, Stone E, Warren G, Cummings KM. Cannabis Use, Lung Cancer, and Related Issues. Journal of thoracic oncology 2018; 13(2): 480-487. [DOI:10.1016/j.jtho.2017.12.013]
21. Seltzer ES, Watters AK, Mackenzie D, Granat LM, Zhang D. Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers 2020; 12(11): 3203. [DOI:10.3390/cancers12113203]
22. Solinas M, Cinquina V, Parolaro D. Cannabidiol and Cancer-An Overview of the Preclinical Data. In book Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor; 2015; doi:10.5772/59193. [DOI:10.5772/59193]
23. Noreen N, Muhammad F, Akhtar B, Azam F, Anwar MI. Is Cannabidiol a promising substance for new drug development? A review of its potential therapeutic applications. Critical reviews in eukaryotic gene expression 2018; 28(1): 73-86. [DOI:10.1615/CritRevEukaryotGeneExpr.2018021528]
24. Boyacıoğlu Ö, Bilgiç E, Varan C, Bilensoy E, Nemutlu E, Sevim D, Kocaefe Ç, Korkusuz P. ACPA decreases non-small cell lung cancer line growth through Akt/PI3K and JNK pathways in vitro. Cell death and disease 2021; 12(1): 56. [DOI:10.1038/s41419-020-03274-3]
25. Preet A, Ganju RK, Groopman JE. Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008 273 2007; 27(3): 339-346. [DOI:10.1038/sj.onc.1210641]
26. Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. The oncologist 2019; 24(4): 549-554. [DOI:10.1634/theoncologist.2018-0383]
27. Winkler K, Ramer R, Dithmer S, Ivanov I, Merkord J, Hinz B. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget 2016; 7(12): 15047-15064. [DOI:10.18632/oncotarget.7592]
28. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE, Ganju RK. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Cancer prevention research 2011; 4(1): 65-75. [DOI:10.1158/1940-6207.CAPR-10-0181]
29. Kapoor S. The inhibitory effects of cannabidiol on systemic malignant tumors. Journal of pain and symptom management 2013; 45(4): e1. [DOI:10.1016/j.jpainsymman.2013.02.002]
30. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochemical pharmacology 2010; 79(7): 955-966. [DOI:10.1016/j.bcp.2009.11.007]
31. Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Molecular cancer therapeutics 2013; 12(1): 69-82. [DOI:10.1158/1535-7163.MCT-12-0335]
32. Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical pharmacology 2014; 92(2): 312-325. [DOI:10.1016/j.bcp.2014.07.014]
33. Todorova J, Lazarov LI, Petrova M, Tzintzarov A, Ugrinova I. The antitumor activity of cannabidiol on lung cancer cell lines A549 and H1299: the role of apoptosis. Biotechnology and biotechnological equipment 2021; 35: 873-879. [DOI:10.1080/13102818.2021.1915870]
34. Choi WH, Park H Do, Baek SH, Chu JP, Kang MH, Mi YJ. Cannabidiol induces cytotoxicity and cell death via apoptotic pathway in cancer cell lines. Biomoeules and therapiutics 2008; 16: 87-94. [DOI:10.4062/biomolther.2008.16.2.087]
35. Ramer R, Fischer S, Haustein M, Manda K, Hinz B. Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochemical pharmacology 2014; 91(2): 202-216. [DOI:10.1016/j.bcp.2014.06.017]
36. Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, Borchert P, Schmuhl E, Linnebacher M, Hinz B. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB journal 2012; 26(4): 1535-1548. [DOI:10.1096/fj.11-198184]
37. Ramer R, Rohde A, Merkord J, Rohde H, Hinz B. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharmaceutical research 2010; 27(10): 2162-2174. [DOI:10.1007/s11095-010-0219-2]
38. Milian L, Mata M, Alcacer J, Oliver M, Sancho-Tello M, de Llano JJM, Camps C, Galbis J, Carretero J, Carda C. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS one 2020; 15(2): e0228909. [DOI:10.1371/journal.pone.0228909]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |